LIPO — Lipella Pharmaceuticals Income Statement
0.000.00%
- $3.48m
- $1.37m
- $0.45m
- 32
- 18
- 19
- 12
Annual income statement for Lipella Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.695 | 0.962 | 0.259 | 0.184 | 0.45 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 0.749 | 1.02 | 2.18 | 2.77 | 5.2 |
Operating Profit | -0.054 | -0.057 | -1.92 | -2.59 | -4.75 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.062 | -0.062 | -1.87 | -2.6 | -4.62 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.062 | -0.062 | -1.87 | -2.6 | -4.62 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.062 | -0.062 | -1.87 | -2.6 | -4.62 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -0.062 | -0.062 | -1.87 | -2.6 | -4.62 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.011 | -0.011 | -0.325 | -0.64 | -0.769 |
Dividends per Share |